Literature DB >> 20824706

Randomized healthservices study of human papillomavirus-based management of low-grade cytological abnormalities.

Lena Dillner1, Levent Kemetli, Kristina Elfgren, Gordana Bogdanovic, Pia Andersson, Agneta Carlsten-Thor, Sonia Andersson, Elisabeth Persson, Eva Rylander, Lena Grillner, Joakim Dillner, Sven Törnberg.   

Abstract

Human papillomavirus (HPV)-based management of women with borderline atypical squamous cells of undetermined significance (ASCUS) or mildly abnormal cervical intraepithelial neoplasia (CINI) cervical cytology has been extensively studied in the research setting. We wished to assess safety and health care resource use of a real-life health care policy using HPV triaging. All 15 outpatient clinics involved in the organized population-based screening program in Stockholm, Sweden screening program were randomized to either continue with prior policy (colposcopy of all women with ASCUS/CINI) or to implement a policy with HPV triaging and colposcopy only of HPV-positive women. The trial enrolled the 3,319 women who were diagnosed with ASCUS (n = 1,335) or CINI (n = 1,984) in Stockholm during 17th March 2003 to 16th January 2006. Detection of high-grade cervical lesions (CINII+) and health care cost consumption was studied by registry linkages. The proportion of histopathology-verified CINII+ was similar for the two policies (395 of 1,752 women (22.5%; 95% Confidence interval [CI]: 20.6-24.6%) had CINII+ diagnosed with HPV triaging policy, 318 of 1,567 women (20.3%; 95%CI: 18.3-22.4%) had CINII+ with colposcopy policy). Sixty-four percent of women with ASCUS and 77% of women with CINI were HPV positive. HPV-positivity was age-dependent, with 81% of women below 35 years of age and 44% of women above 45 years of age testing HPV-positive. HPV triaging was cost-effective only above 35 years of age. In conclusion, a real-life randomized healthservices study of HPV triaging of women with ASCUS/CINI demonstrated similar detection of CINII+ as colposcopy of all women.
Copyright © 2010 UICC.

Entities:  

Mesh:

Year:  2010        PMID: 20824706     DOI: 10.1002/ijc.25649

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.

Authors:  Ameli Tropé; Katrine D Sjøborg; Mari Nygård; Kjetil Røysland; Suzanne Campbell; G Cecilie Alfsen; Christine M Jonassen
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

2.  Triage of women with low-grade cervical lesions--HPV mRNA testing versus repeat cytology.

Authors:  Sveinung Wergeland Sørbye; Marc Arbyn; Silje Fismen; Tore Jarl Gutteberg; Elin Synnøve Mortensen
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

3.  HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.

Authors:  Sveinung Wergeland Sørbye; Marc Arbyn; Silje Fismen; Tore Jarl Gutteberg; Elin Synnøve Mortensen
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

4.  Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type.

Authors:  Maria Persson; K Miriam Elfström; Sven-Erik Olsson; Joakim Dillner; Sonia Andersson
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

5.  Barriers to HPV immunization among blacks and latinos: a qualitative analysis of caregivers, adolescents, and providers.

Authors:  Ingrid T Katz; Laura M Bogart; Chong Min Fu; Yingna Liu; Joanne E Cox; Ronald C Samuels; Tami Chase; Pamela Schubert; Mark A Schuster
Journal:  BMC Public Health       Date:  2016-08-25       Impact factor: 3.295

6.  Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study.

Authors:  Ingrid Norman; Anders Hjerpe; Joakim Dillner
Journal:  BMJ Open       Date:  2017-12-14       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.